ES2525205T3 - Vacuna para su uso en inmunoterapia tumoral - Google Patents

Vacuna para su uso en inmunoterapia tumoral Download PDF

Info

Publication number
ES2525205T3
ES2525205T3 ES11188494.6T ES11188494T ES2525205T3 ES 2525205 T3 ES2525205 T3 ES 2525205T3 ES 11188494 T ES11188494 T ES 11188494T ES 2525205 T3 ES2525205 T3 ES 2525205T3
Authority
ES
Spain
Prior art keywords
vaccine
tumor immunotherapy
immunotherapy
vaccine preparation
pbmc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11188494.6T
Other languages
English (en)
Inventor
Werner Lubitz
Pavol Kudela
Jaroslav Michalek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2525205T3 publication Critical patent/ES2525205T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/456—Escherichia; Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oncology (AREA)

Abstract

Preparación de vacuna que comprende: (i) células presentadoras de antígenos profesionales, (ii) antígenos asociados con tumores, y (iii) fantasmas bacterianos para su uso en inmunoterapia

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
E11188494
27-11-2014
Prueba
Criterio para pasar el control de calidad
Pureza de CD (%)
70-100 %
Contaminación de células
CD3 (%) Cantidad total (CD3+ + CD19+) 0-30%
CD19 (%)
Fenotipo de CD*
CD80 (%) 60-100 %
CD86 (%)
60-100 %
CMH clase II (%)
60-100 %
CD83 (%)
60-100 %
CD14 (%)
0-40%
Producción de IL-12 (pg/ml)
≥ 100 pg/ml
MLR alogénico -linfocitos T activados (%)**
Relación CD:PBMC 1:5 ≥ 30 %
Relación CD:PBMC 1:10
≥ 30 %
Relación CD:PBMC 1:20
≥ 15%
* al menos 3 de 5 marcadores fenotípicos deben cumplir los criterios para pasar el control de calidad antes de la administración de preparación de vacuna antitumoral a un paciente **al menos 2 de las 3 proporciones examinadas de CD:PBMC en las pruebas de MLR alogénico deben cumplir los criterios para pasar el control de calidad antes de la administración de preparación de vacuna antitumoral a un paciente
9

Claims (1)

  1. imagen1
ES11188494.6T 2011-11-09 2011-11-09 Vacuna para su uso en inmunoterapia tumoral Active ES2525205T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11188494.6A EP2591798B1 (en) 2011-11-09 2011-11-09 Vaccine for use in tumor immunotherapy

Publications (1)

Publication Number Publication Date
ES2525205T3 true ES2525205T3 (es) 2014-12-18

Family

ID=44992693

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11188494.6T Active ES2525205T3 (es) 2011-11-09 2011-11-09 Vacuna para su uso en inmunoterapia tumoral

Country Status (9)

Country Link
US (1) US9790260B2 (es)
EP (2) EP2591798B1 (es)
JP (1) JP6029677B2 (es)
CN (1) CN104066443A (es)
AU (1) AU2012334095B2 (es)
ES (1) ES2525205T3 (es)
HK (1) HK1202070A1 (es)
PL (1) PL2591798T3 (es)
WO (1) WO2013068406A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016011347A1 (en) * 2014-07-17 2016-01-21 The Trustees Of The University Of Pennsylvania Multi-dose injection ready dendritic cell vaccines and combination therapy for cancer
US20160129097A1 (en) * 2014-11-06 2016-05-12 Jeremy Delk Method of processing a veterinary tumor vaccine and a veterinary tumor vaccine processing kit
CN104606665A (zh) * 2015-02-13 2015-05-13 闫书印 一种基于骨髓穿刺术的用于骨转移疼痛的治疗配方
CN105126094A (zh) * 2015-08-13 2015-12-09 安徽农业大学 一种拟态弧菌菌影疫苗及其制备方法和应用
EP3195878A1 (en) * 2016-01-22 2017-07-26 Werner Lubitz Bacterial ghosts for the treatment of cancer
CA3086832A1 (en) * 2018-01-03 2019-07-11 Qu Biologics Inc. Innate targeting of adoptive cellular therapies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117125A (en) 1977-06-24 1978-09-26 Smithkline Corporation 7-Acylamino-3-[1-[2-(carboxymethylamino]ethyl) tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acids
DE19732829A1 (de) 1997-07-30 1999-02-04 Lubitz Werner Prof Dr Sekretion von trägergebundenen Proteinen in das Periplasma und in den extrazellulären Raum
DE19909770A1 (de) * 1999-03-05 2000-09-07 Werner Lubitz Bakterienghosts als Träger- und Targetingvehikel
DE10003241A1 (de) 2000-01-26 2001-08-02 Werner Lubitz Verschließen von Bakterienghosts
US7037500B1 (en) * 2000-09-08 2006-05-02 The Trustees Of Columbia University In The City Of New York Method for using phagocytic particles and ATP receptors to deliver antigens to MHC class I receptors to induce immunity against microbial pathogens or tumors or to suppress immunity
CA2453518C (en) 2001-07-11 2010-02-02 Werner Lubitz Nucleic acid-free bacterial ghost preparation formed by co-expression of lytic and nuclease genes
KR101241272B1 (ko) * 2002-12-16 2013-03-15 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 면역 요법으로서의 효모계 백신
WO2007016130A2 (en) 2005-07-27 2007-02-08 Lipid Sciences, Inc. A method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response
US20110172826A1 (en) * 2005-12-14 2011-07-14 Amodei Dario G Device including altered microorganisms, and methods and systems of use
CA2638815A1 (en) 2006-02-02 2007-08-16 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response
AU2007269245B2 (en) 2006-06-30 2012-04-12 Baylor Research Institute Dendritic cells generated using GM-CSF and interferon alpha and loaded with heat-treated and killed cancer cells
EP1897557A1 (en) * 2006-09-07 2008-03-12 Helmholtz-Zentrum für Infektionsforschung GmbH Use of glycolipids as adjuvants
WO2009090093A1 (en) 2008-01-18 2009-07-23 Werner Lubitz Bacterial ghost (bg) production process using betapropiolactone (blp) for final inactivation
EP3320915A1 (en) 2009-04-17 2018-05-16 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods

Also Published As

Publication number Publication date
AU2012334095A1 (en) 2014-05-29
NZ624069A (en) 2015-10-30
CN104066443A (zh) 2014-09-24
PL2591798T3 (pl) 2015-04-30
JP2015504423A (ja) 2015-02-12
US20130115245A1 (en) 2013-05-09
HK1202070A1 (zh) 2015-09-18
WO2013068406A1 (en) 2013-05-16
EP2591798A1 (en) 2013-05-15
EP2776060A1 (en) 2014-09-17
US9790260B2 (en) 2017-10-17
JP6029677B2 (ja) 2016-11-24
EP2591798B1 (en) 2014-11-19
AU2012334095B2 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
ES2525205T3 (es) Vacuna para su uso en inmunoterapia tumoral
Sun et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid
Takei et al. Dendritic cells maturation promoted by M1 and M4, end products of steroidal ginseng saponins metabolized in digestive tracts, drive a potent Th1 polarization
Liu et al. Impaired production of TNF-α by dendritic cells of older adults leads to a lower CD8+ T cell response against influenza
Dauer et al. FastDC derived from human monocytes within 48 h effectively prime tumor antigen-specific cytotoxic T cells
JP2010523141A5 (es)
Massa et al. Fast dendritic cells stimulated with alternative maturation mixtures induce polyfunctional and long-lasting activation of innate and adaptive effector cells with tumor-killing capabilities
Kolanowski et al. Comparison of media and serum supplementation for generation of monophosphoryl lipid A/interferon-γ–matured type I dendritic cells for immunotherapy
Baek et al. Dendritic cell (DC) vaccine in mouse lung cancer minimal residual model; comparison of monocyte-derived DC vs. hematopoietic stem cell derived-DC
KR20240063197A (ko) Tcr 감마 델타 양성 t 세포의 생산 방법
US9089593B2 (en) Dendritic cell tumor injection (DCTI) therapy
Lehner et al. Functional characterization of monocyte-derived dendritic cells generated under serumfree culture conditions
WO2020223821A1 (en) Miha peptide combinations and uses thereof
Chang et al. Cord blood stem-cell-derived dendritic cells generate potent antigen-specific immune responses and anti-tumour effects
Mac Keon et al. Vaccination with dendritic cells charged with apoptotic/necrotic B16 melanoma induces the formation of subcutaneous lymphoid tissue
Feng et al. Adoptive transferred hepatic stellate cells attenuated drug-induced liver injury by modulating the rate of regulatory T cells/T helper 17 cells
Milano et al. An improved protocol for generation of immuno-potent dendritic cells through direct electroporation of CD14+ monocytes
Jin et al. Epstein–Barr virus induces the differentiation of semi-mature dendritic cells from cord blood monocytes
WO2018024893A1 (en) Invariant foxp3+ regulatory t cells and therapeutic uses thereof
CN105219723A (zh) 一种用于激活胃癌特异性免疫反应的试剂盒
CN105219727A (zh) 一种用于激活结直肠癌特异性免疫反应的试剂盒
CN105219714A (zh) 一种用于激活肺癌特异性免疫反应的试剂盒
Néron et al. Effective in vitro expansion of CD40-activated human B lymphocytes in a defined bovine protein-free medium
Law et al. Human axillary lymph node T follicular helper (Tfh) and Precursor‐Tfh cells exhibit functional flexibility following seasonal influenza vaccination
Schmetzer¹ et al. Perspectives for Future Therapies'